Direct-to-consumer telehealth statistics 2026: Hims & Hers, Ro, LifeMD and GLP-1 programs

Hims & Hers revenue in 2025, up 59% year over year¹

Hims & Hers net income in 2025¹

Adjusted EBITDA was $318.0 million. Net income was affected by a $68.0 million valuation allowance change.

Hims & Hers revenue in Q2 2026, up 38% from $544.8 million in Q2 2025²

US revenue was $621.8 million, up 16%. The company reported a Q2 2026 net loss of $86.3 million.

Hims & Hers subscribers at the end of Q2 2026, up 19% from 2,439,000 a year earlier²

Subscribers were 2,511,000 at the end of 2025, up 13%.

Hims & Hers monthly revenue per average subscriber in Q2 2026, up 21% from $76²

Hims & Hers full-year 2026 revenue guidance, raised in August 2026²

In February 2026 the company had guided to $2.7 billion to $2.9 billion.

Hims & Hers revenue outside the US in Q2 2026, up from $7.5 million a year earlier²

The company said its June 2026 acquisition of Eucalyptus helped international growth.

Hims & Hers subscribers were using a personalized treatment at the end of 2025, up more than 30% year over year³

The company also said over 20% of subscribers were addressing multiple conditions on its platform.

telehealth consultations facilitated by Hims & Hers since its founding, as of its 2025 annual report⁴

The company operates in the US, Canada, the UK and parts of the EU.

time it took Hims & Hers weight loss category to reach $100 million in annual revenue³

The company said this compared with 3 to 4 years for its sexual health and hair loss categories. It did not disclose a weight loss revenue figure.

of Hims & Hers 2025 revenue came from non-GLP-1 offerings, according to the company³

is how Hims & Hers described its US access to compounded GLP-1 medications after shifting its weight loss offering in Q1 2026⁵

Hims & Hers Q1 2026 revenue was $608.1 million, up 4%, while US revenue fell 8%.

LifeMD Weight Management Program subscribers at the end of Q2 2026⁶

of new LifeMD weight management patients begin treatment with branded GLP-1 therapies (Q2 2026)⁶

LifeMD said it is effectively at the end of its transition away from compounded GLP-1 medications.

WW International (WeightWatchers) clinical subscribers at the end of Q2 2026, up 55.7% year over year⁷

WW total subscribers were 2,489,000, down 21.4%.

WW International clinical subscription revenue in Q2 2026, up 30.4% year over year⁷

Total WW revenue was $162.3 million.

estimated annualized revenue for Ro in 2024, up 66% from $360 million in 2023⁸

Ro is private and does not publish financials. This is a third-party estimate by Sacra.

valuation of Ro in its most recent priced funding round, in February 2022⁸

Sacra reports Ro has raised about $1.0 billion in primary capital.

LifeMD revenue in 2025, up 25% from 2024⁹

LifeMD had 322,872 active subscribers at the end of 2025, up 16%.

LifeMD active subscribers at the end of Q2 2026, up 20% year over year⁶

Q2 2026 revenue was $47.3 million, down 4%, and LifeMD cut its 2026 revenue guidance to $205.5 million to $212.5 million.

Teladoc Health BetterHelp segment revenue in Q2 2026, down 12% year over year¹⁰

BetterHelp averaged 346,000 paying users in the quarter, down 11%.

projected size of the US direct-to-consumer telehealth services market by 2030, growing at a 30.3% compound annual rate¹¹

Third-party market research estimate; definitions vary widely between research firms.

monthly self-pay price of the Wegovy pill starting dose (1.5 mg) at launch in January 2026¹²

The 4 mg dose was $149 through April 15, 2026, then $199. The highest doses are $299 a month.

Wegovy pill prescriptions between its January 5, 2026 launch and June 2, 2026¹³

Counts partner-reported paid claims only.

monthly copay for Wegovy for eligible Medicare beneficiaries through the Medicare GLP-1 Bridge, which started July 1, 2026¹³

The program runs through the end of 2027.

monthly self-pay price for the Zepbound 2.5 mg single-dose vial through LillyDirect, after Lilly's December 2025 price cut¹⁴

The 5 mg dose is $399 and other approved doses are $449 a month in the Zepbound Self Pay Journey Program. Figures taken from the search listing for the Lilly release because the release page blocked direct access.

telehealth providers named by Novo Nordisk as offering the Wegovy pill at launch: Ro, LifeMD and Weight Watchers¹²

of US adults who have taken a GLP-1 drug said they got it from an online provider or website (2025)¹⁵

76% got it from a doctor and 9% from a medical spa or aesthetic center. Respondents could give more than one source. Poll fielded October 27 to November 2, 2025.

of US adults said they were currently taking a GLP-1 drug in late 2025, up 6 percentage points from May 2024¹⁵

18% said they had ever used one.

of GLP-1 users said the drugs were difficult to afford (2025)¹⁵

27% of insured users said they paid the full cost themselves.

of adults not taking a GLP-1 said they would be interested in taking one to lose weight (2025)¹⁵

Interest rose to 43% among adults diagnosed with overweight or obesity who were not taking one.